255 related articles for article (PubMed ID: 34070502)
1. Roles of Nrf2 in Gastric Cancer: Targeting for Therapeutic Strategies.
Farkhondeh T; Pourbagher-Shahri AM; Azimi-Nezhad M; Forouzanfar F; Brockmueller A; Ashrafizadeh M; Talebi M; Shakibaei M; Samarghandian S
Molecules; 2021 May; 26(11):. PubMed ID: 34070502
[TBL] [Abstract][Full Text] [Related]
2. Nrf2 overexpression predicts prognosis and 5-FU resistance in gastric cancer.
Hu XF; Yao J; Gao SG; Wang XS; Peng XQ; Yang YT; Feng XS
Asian Pac J Cancer Prev; 2013; 14(9):5231-5. PubMed ID: 24175806
[TBL] [Abstract][Full Text] [Related]
3. BDH2 triggers ROS-induced cell death and autophagy by promoting Nrf2 ubiquitination in gastric cancer.
Liu JZ; Hu YL; Feng Y; Jiang Y; Guo YB; Liu YF; Chen X; Yang JL; Chen YY; Mao QS; Xue WJ
J Exp Clin Cancer Res; 2020 Jun; 39(1):123. PubMed ID: 32605589
[TBL] [Abstract][Full Text] [Related]
4. Emerging role of NRF2 in ROS-mediated tumor chemoresistance.
Xue D; Zhou X; Qiu J
Biomed Pharmacother; 2020 Nov; 131():110676. PubMed ID: 32858502
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological significance of nuclear factor (erythroid-2)-related factor 2 (Nrf2) expression in gastric cancer.
Kawasaki Y; Ishigami S; Arigami T; Uenosono Y; Yanagita S; Uchikado Y; Kita Y; Nishizono Y; Okumura H; Nakajo A; Kijima Y; Maemura K; Natsugoe S
BMC Cancer; 2015 Jan; 15():5. PubMed ID: 25588809
[TBL] [Abstract][Full Text] [Related]
6. Gene expression profiling for analysis acquired oxaliplatin resistant factors in human gastric carcinoma TSGH-S3 cells: the role of IL-6 signaling and Nrf2/AKR1C axis identification.
Chen CC; Chu CB; Liu KJ; Huang CY; Chang JY; Pan WY; Chen HH; Cheng YH; Lee KD; Chen MF; Kuo CC; Chen LT
Biochem Pharmacol; 2013 Oct; 86(7):872-87. PubMed ID: 23933386
[TBL] [Abstract][Full Text] [Related]
7. Correlation Between Nuclear Factor E2-Related Factor 2 Expression and Gastric Cancer Progression.
Zheng H; Nong Z; Lu G
Med Sci Monit; 2015 Sep; 21():2893-9. PubMed ID: 26410168
[TBL] [Abstract][Full Text] [Related]
8. Amplified in breast cancer 1 enhances human cholangiocarcinoma growth and chemoresistance by simultaneous activation of Akt and Nrf2 pathways.
Chen Q; Li W; Wan Y; Xia X; Wu Q; Chen Y; Lai Z; Yu C; Li W
Hepatology; 2012 Jun; 55(6):1820-9. PubMed ID: 22213475
[TBL] [Abstract][Full Text] [Related]
9. Nrf2 overexpression is associated with P-glycoprotein upregulation in gastric cancer.
Jeddi F; Soozangar N; Sadeghi MR; Somi MH; Shirmohamadi M; Eftekhar-Sadat AT; Samadi N
Biomed Pharmacother; 2018 Jan; 97():286-292. PubMed ID: 29091877
[TBL] [Abstract][Full Text] [Related]
10. The balance between NRF2/GSH antioxidant mediated pathway and DNA repair modulates cisplatin resistance in lung cancer cells.
Silva MM; Rocha CRR; Kinker GS; Pelegrini AL; Menck CFM
Sci Rep; 2019 Nov; 9(1):17639. PubMed ID: 31776385
[TBL] [Abstract][Full Text] [Related]
11. "NRF2 addiction" in lung cancer cells and its impact on cancer therapy.
Hammad A; Namani A; Elshaer M; Wang XJ; Tang X
Cancer Lett; 2019 Dec; 467():40-49. PubMed ID: 31574294
[TBL] [Abstract][Full Text] [Related]
12. Ginsenoside Rd reverses cisplatin resistance in non-small-cell lung cancer A549 cells by downregulating the nuclear factor erythroid 2-related factor 2 pathway.
Chian S; Zhao Y; Xu M; Yu X; Ke X; Gao R; Yin L
Anticancer Drugs; 2019 Sep; 30(8):838-845. PubMed ID: 31415285
[TBL] [Abstract][Full Text] [Related]
13. A ruthenium(II)-curcumin compound modulates NRF2 expression balancing the cancer cell death/survival outcome according to p53 status.
Garufi A; Baldari S; Pettinari R; Gilardini Montani MS; D'Orazi V; Pistritto G; Crispini A; Giorno E; Toietta G; Marchetti F; Cirone M; D'Orazi G
J Exp Clin Cancer Res; 2020 Jun; 39(1):122. PubMed ID: 32605658
[TBL] [Abstract][Full Text] [Related]
14. [Nrf2--Two Faces of Antioxidant System Regulation].
Pastorek M; Müller P; Vojtěšek B
Klin Onkol; 2015; 28 Suppl 2():2S26-31. PubMed ID: 26374155
[TBL] [Abstract][Full Text] [Related]
15. NRF2 through RPS6 Activation Is Related to Anti-HER2 Drug Resistance in
Gambardella V; Gimeno-Valiente F; Tarazona N; Martinez-Ciarpaglini C; Roda D; Fleitas T; Tolosa P; Cejalvo JM; Huerta M; Roselló S; Castillo J; Cervantes A
Clin Cancer Res; 2019 Mar; 25(5):1639-1649. PubMed ID: 30504425
[TBL] [Abstract][Full Text] [Related]
16. The role of NF-E2-related factor 2 in predicting chemoresistance and prognosis in advanced non-small-cell lung cancer.
Yang H; Wang W; Zhang Y; Zhao J; Lin E; Gao J; He J
Clin Lung Cancer; 2011 May; 12(3):166-71. PubMed ID: 21663859
[TBL] [Abstract][Full Text] [Related]
17. Crosstalk between Nrf2 and YAP contributes to maintaining the antioxidant potential and chemoresistance in bladder cancer.
Ciamporcero E; Daga M; Pizzimenti S; Roetto A; Dianzani C; Compagnone A; Palmieri A; Ullio C; Cangemi L; Pili R; Barrera G
Free Radic Biol Med; 2018 Feb; 115():447-457. PubMed ID: 29248722
[TBL] [Abstract][Full Text] [Related]
18. Combined Evaluation of Expression of CXCR4 and Nrf2 as Prognostic Factor for Patients with Gastric Carcinoma.
Yu S; Wu T; Wang J; Cheng C; Wang J; Sun L; Liu C; Cao G; Hu T
Anticancer Agents Med Chem; 2018; 18(3):388-393. PubMed ID: 29110625
[TBL] [Abstract][Full Text] [Related]
19. NRF2/SHH signaling cascade promotes tumor-initiating cell lineage and drug resistance in hepatocellular carcinoma.
Leung HW; Lau EYT; Leung CON; Lei MML; Mok EHK; Ma VWS; Cho WCS; Ng IOL; Yun JP; Cai SH; Yu HJ; Ma S; Lee TKW
Cancer Lett; 2020 Apr; 476():48-56. PubMed ID: 32061952
[TBL] [Abstract][Full Text] [Related]
20. Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2) Inhibition: An Emerging Strategy in Cancer Therapy.
Jiang ZY; Lu MC; You QD
J Med Chem; 2019 Apr; 62(8):3840-3856. PubMed ID: 30444366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
